Parecoxib and Imrecoxib Sequential Therapy: A Breakthrough in Managing Severe Acute Pancreatitis
Posted inClinical Updates Critical Care Emergency Medicine Gastroenterology news Specialties

Parecoxib and Imrecoxib Sequential Therapy: A Breakthrough in Managing Severe Acute Pancreatitis

This multicentre trial shows sequential use of COX-2 inhibitors parecoxib and imrecoxib significantly reduces severe acute pancreatitis (SAP) incidence, shortens organ failure duration, lowers local complications, and decreases 30-day mortality, with a good safety profile.
Patritumab Deruxtecan Shows Promising Efficacy in HR+HER2− Advanced Breast Cancer After CDK4/6 Inhibitor Failure: Insights from ICARUS-BREAST01 Phase 2 Trial
Posted inClinical Updates news OB/GYN & Women's Health Oncology Specialties

Patritumab Deruxtecan Shows Promising Efficacy in HR+HER2− Advanced Breast Cancer After CDK4/6 Inhibitor Failure: Insights from ICARUS-BREAST01 Phase 2 Trial

The ICARUS-BREAST01 phase 2 trial demonstrated patritumab deruxtecan's efficacy and manageable safety in HR+HER2− metastatic breast cancer post-CDK4/6 inhibitors, highlighting key biomarkers linked to response and resistance.
Reevaluating Beta-Blocker Therapy Post-Myocardial Infarction with Preserved Ejection Fraction: Insights from Recent Trials and Meta-Analyses
Posted inCardiology Clinical Updates news Specialties

Reevaluating Beta-Blocker Therapy Post-Myocardial Infarction with Preserved Ejection Fraction: Insights from Recent Trials and Meta-Analyses

Recent evidence challenges the routine use of long-term beta-blockers after myocardial infarction in patients with preserved ejection fraction, highlighting comparable outcomes with or without therapy and raising safety and efficacy considerations in contemporary practice.